Entrada Therapeutics (TRDA)

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	82.00 mm	82.00 mm	82.00 mm	82.00 mm	82.00 mm	82.00 mm
Cash burn (monthly)	35.73 mm	(no burn)	7.22 mm	(no burn)	8.09 mm	1.16 mm
Cash used (since last report)	162.85 mm	n/a	32.90 mm	n/a	36.86 mm	5.30 mm
Cash remaining	-80.86 mm	n/a	49.10 mm	n/a	45.14 mm	76.70 mm
Runway (months of cash)	-2.3	n/a	6.8	n/a	5.6	65.9

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q3 2024

TRDA institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	102	87	+17.2%
Opened positions	24	18	+33.3%
Closed positions	9	11	-18.2%
Increased positions	41	41	–
Reduced positions	18	11	+63.6%

13F shares	Current	Prev Q	Change
Total value	428.69 bn	377.10 bn	+13.7%
Total shares	40.07 mm	39.64 mm	+1.1%
Total puts	16.40 k	0.00	NEW
Total calls	34.50 k	100.00	+34400.0%
Total put/call ratio	0.5	–	–

Largest owners	Shares	Value	Change
Baker Bros. Advisors	4.87 mm	$77.76 bn	0.0%
MPM Asset Management	4.43 mm	$70.72 bn	0.0%
5AM Venture Management	4.41 mm	$70.45 bn	0.0%
5AM Ventures V	3.28 mm	$83.47 mm	0.0%
T. Rowe Price	3.05 mm	$48.73 mm	-2.7%
Roche Finance	2.74 mm	$42.10 mm	0.0%
MPM BioVentures 2014	2.21 mm	$56.38 mm	0.0%
BlackRock	1.82 mm	$29.13 bn	NEW
FMR	1.74 mm	$27.86 bn	-4.7%
MRL Ventures Fund	1.74 mm	$29.79 mm	0.0%

Largest transactions	Shares	Bought/sold	Change
BlackRock	1.82 mm	+1.82 mm	NEW
BLK BlackRock	0.00	-1.69 mm	EXIT
Redmile	0.00	-560.97 k	EXIT
American Century Companies	50.73 k	-334.25 k	-86.8%
JHG Janus Henderson	1.71 mm	+161.96 k	+10.5%
Dimensional Fund Advisors	95.41 k	+95.41 k	NEW
Vanguard	1.22 mm	+93.56 k	+8.3%
FMR	1.74 mm	-85.67 k	-4.7%
Arrowstreet Capital, Limited Partnership	99.70 k	+85.39 k	+596.8%
T. Rowe Price	3.05 mm	-84.89 k	-2.7%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

TRDA insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
11 Dec 24	MPM Bioventures 2018	Common Stock	Sell	Dispose S	Yes	No	20.23	21,787	440.75 k	4,381,062
11 Dec 24	MPM BioVentures 2014	Common Stock	Sell	Dispose S	Yes	No	20.23	21,787	440.75 k	4,381,062
10 Dec 24	MPM Bioventures 2018	Common Stock	Sell	Dispose S	Yes	No	20.77	22,935	476.36 k	4,402,849
10 Dec 24	MPM BioVentures 2014	Common Stock	Sell	Dispose S	Yes	No	20.77	22,935	476.36 k	4,402,849
3 Dec 24	Natarajan Sethuraman	Common Stock	Sell	Dispose S	No	Yes	20.1475	11,703	235.79 k	144,997
2 Dec 24	Natarajan Sethuraman	Common Stock	Sell	Dispose S	No	Yes	20.2626	4,088	82.83 k	156,700
2 Dec 24	Kory James Wentworth	Common Stock	Sell	Dispose S	No	Yes	19.9956	5,000	99.98 k	73,849
2 Dec 24	Kory James Wentworth	Common Stock	Option exercise	Acquire M	No	Yes	2.1	5,000	10.50 k	78,849
2 Dec 24	Kory James Wentworth	Stock Option Common Stock	Option exercise	Dispose M	No	Yes	2.1	5,000	10.50 k	31,157
29 Nov 24	Natarajan Sethuraman	Common Stock	Sell	Dispose S	No	Yes	20	100	2.00 k	160,788

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

HC Wainwright & Co. Reiterates Buy on Entrada Therapeutics, Maintains $20 Price Target

4 Feb 25

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Entrada Therapeutics (NASDAQ:TRDA) with a Buy and maintains $20 price target.

Entrada Therapeutics Gets UK Approval to Launch Phase 1/2 Trial for Duchenne Muscular Dystrophy Treatment

3 Feb 25

Entrada Therapeutics, Inc. (NASDAQ:TRDA) today announced it had received authorization from the United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA) and Research Ethics Committee for its Clinical

Press releases

From Benzinga Pro

Azenta Announces the Election of Dipal Doshi to its Board of Directors

30 Jan 25

BURLINGTON, Mass., Jan. 30, 2025 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today announced that Dipal Doshi, Chief Executive Officer of Entrada Therapeutics (NASDAQ:TRDA) and a recognized leader in the biotechnology and